The National Cancer Society Malaysia has issued an urgent call for a comprehensive national co-screening strategy to tackle the growing threat of cardio-renal-metabolic diseases, which encompass cardiovascular illness, kidney dysfunction and metabolic disorders such as diabetes. The organisation's push comes as evidence mounts that these interconnected conditions are increasingly prevalent among Malaysians and frequently develop together, creating compounding health risks that existing fragmented healthcare approaches fail to address adequately.
The scope of the challenge became evident through the NCSM-Boehringer Ingelheim Saring@Komuniti Project, executed with support from the Ministry of Health. The initiative screened 5,000 individuals from disadvantaged communities across the Klang Valley last year, revealing an alarming concentration of overlapping cardiovascular, kidney and metabolic complications. The findings paint a sobering picture of Malaysia's chronic disease landscape, demonstrating that nearly nine in ten individuals carry at least two cardio-renal-metabolic risk factors simultaneously. This interconnected nature of the diseases—whereby they share common underlying causes and accelerate each other's progression—suggests that siloed treatment approaches are fundamentally inadequate for the Malaysian context.
The screening data underscores the severity of metabolic disease in particular. Among the 5,000 participants, 41.3 per cent were classified as obese and 28.8 per cent as overweight, while blood sugar disorders were rampant: 34.5 per cent had pre-diabetes and 35.1 per cent had diabetes. Most striking, 97.8 per cent of all participants presented with at least one cardio-renal-metabolic risk factor. These figures are not simply academic abstractions; they represent hundreds of thousands of Malaysians whose health trajectories remain largely unmonitored and unmanaged, particularly in lower-income and underserved communities where access to regular health screening remains inconsistent.
The burden extends beyond prevalence to healthcare system strain. Chronic kidney disease prevalence in Malaysia has surged from 9.1 per cent in 2011 to 15.5 per cent in 2019, a trajectory that signals accelerating disease incidence across the population. More dramatically, the number of Malaysians dependent on dialysis has increased more than threefold over the past two decades. These metrics reveal not only the expansion of disease but also the mounting financial and human resource pressures on Malaysia's healthcare infrastructure, which must provide ongoing dialysis, medication management and specialist care for expanding patient cohorts.
A central problem identified by healthcare experts is the delayed detection of these diseases. Current practice typically involves addressing cardiovascular health, kidney function and metabolic disorders independently, with patients often seeing different specialists across different healthcare settings. This fragmentation creates critical blind spots: a patient presenting with elevated blood pressure might be treated for hypertension alone without formal assessment of kidney function or blood sugar regulation, even though these conditions frequently coexist and influence one another. Early identification of the full constellation of risk factors could enable preventive interventions before irreversible organ damage occurs.
Equally problematic are the barriers patients encounter once abnormal screening results are identified. Many individuals do not successfully transition from detection to diagnosis and sustained management. Referral pathways remain inconsistent across public and private healthcare providers, follow-up systems are unreliable, and continuity of care frequently breaks down. For patients in lower-income settings, these structural gaps are particularly acute, as they may lack the resources, information or navigational ability to independently coordinate specialist appointments. Without systematic mechanisms to ensure that screened individuals receive timely diagnosis, initiation of treatment and ongoing monitoring, screening exercises generate awareness of disease but fail to translate into improved health outcomes.
The NCSM's policy recommendations address both detection and care continuity. The organisation advocates expanding integrated co-screening programmes across Malaysia that simultaneously assess cardiovascular, kidney and metabolic risk during routine health encounters. Such an approach would embed standardised cardio-renal-metabolic risk assessments into primary care check-ups, vaccination visits and workplace health programmes. By identifying the full risk profile of each individual rather than checking individual parameters in isolation, Malaysia could move beyond reactive disease management toward preventive intervention. Dr Murallitharan Munisamy, Managing Director of NCSM, emphasised that Malaysia has a narrow window to shift paradigms: early detection must be matched by coordinated follow-up and long-term care systems that ensure patients progress successfully from identification of risk to active management and lifestyle modification.
The second pillar of the strategy involves strengthening referral mechanisms and continuity infrastructure. Rather than leaving patients to navigate the healthcare system independently after an abnormal screening, the proposed system would embed dedicated follow-up protocols, assign care coordinators where appropriate and establish clear communication channels between primary care and specialist services. In the Malaysian context, where many individuals lack health insurance or have limited access to private specialists, such coordinated pathways are essential to prevent screening results from becoming meaningless diagnoses that patients cannot act upon.
The timing of this call is significant. Malaysia, like many middle-income Southeast Asian nations, faces a dual burden of persistent infectious disease threats and rapidly escalating non-communicable disease prevalence. Healthcare budgets remain constrained, and the capacity of the public system is increasingly strained by managing advanced chronic diseases in large patient populations. A proactive national strategy focused on early detection and coordinated intervention could theoretically prevent downstream hospitalisation, dialysis, and cardiovascular events—reducing long-term healthcare expenditure while improving population health outcomes. However, implementing such a strategy requires sustained political commitment, training of healthcare workforce across primary and secondary care settings, and investment in IT infrastructure to enable communication between fragmented healthcare providers.
Boehringer Ingelheim Malaysia, the biopharmaceutical partner in the research project, has reinforced the scientific case for integrated approaches. The company's perspective reflects broader industry recognition that cardiovascular, kidney and metabolic conditions are fundamentally interrelated biological systems rather than independent disease silos. This framing has implications for pharmaceutical development and therapeutic strategy, but more importantly, it legitimises the policy case for healthcare system redesign around integrated rather than categorical disease management.
For Malaysian policymakers and healthcare administrators, the challenge now involves translating evidence and recommendations into actionable policy. The policy briefs launched by NCSM provide a roadmap, but implementation requires coordination between federal and state health authorities, training of primary care providers in risk assessment protocols, and systematic data collection to track screening and follow-up rates. There is also a broader opportunity to position Malaysia as a leader in integrated cardiometabolic screening within Southeast Asia, potentially attracting research partnerships and demonstrating a healthcare innovation model for the region.
The stakes are substantial. Without early detection and coordinated intervention, the burden on individual patients and the healthcare system will continue to accelerate. Patients face advancing disease, premature mortality, and diminished quality of life. The healthcare system faces mounting costs as more individuals progress to advanced disease stages requiring intensive management. Malaysia's economic productivity suffers as working-age adults experience disability and premature illness. The NCSM's call for a national strategy is less a request for additional resources than an evidence-based articulation of how existing resources could be deployed more strategically. The question is not whether Malaysia can afford integrated screening and coordinated care, but whether it can afford to continue managing these interconnected diseases separately.
